MyMyelomaTeam

Darzalex FASPRO (daratumumab hyaluronidase-fihj) is a newer version of daratumumab that can be administered much faster than the original formulation. When combined with other medications, it has shown impressive results in treating multiple myeloma. The drug works by targeting CD38 molecules found in high concentrations on Show Full Answer

Darzalex FASPRO (daratumumab hyaluronidase-fihj) is a newer version of daratumumab that can be administered much faster than the original formulation. When combined with other medications, it has shown impressive results in treating multiple myeloma. The drug works by targeting CD38 molecules found in high concentrations on myeloma cells, helping to destroy them through the body's natural killer cells. While specific combinations of treatments may vary, Darzalex FASPRO has demonstrated effectiveness when used in combination with other myeloma medications. When used with other drugs, it has shown to help about 90% of myeloma patients who had previously tried at least one other treatment option. Your healthcare team can determine if this combination therapy would be appropriate for your specific situation.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

New Treatment Options for Relapsed or Refractory Myeloma

Immunotherapy for Multiple Myeloma: What To Know